Chisaki Mizumoto
Overview
Explore the profile of Chisaki Mizumoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, et al.
Oxf Med Case Reports
. 2025 Jan;
2025(1):omae164.
PMID: 39839700
Craniocervical edema appears soon after chimeric antigen receptor T-cell (CAR-T) therapy in some cases. This phenomenon is often observed right after systemic cytokine release syndrome (CRS), and it is called...
2.
Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, et al.
Br J Haematol
. 2025 Jan;
206(2):766-768.
PMID: 39761673
No abstract available.
3.
Hamada R, Arai Y, Kitawaki T, Nakamura N, Murao M, Matsushita M, et al.
EJHaem
. 2024 Dec;
5(6):1252-1259.
PMID: 39691237
Introduction: Patients undergoing chimeric antigen receptor (CAR) T-cell therapy face prolonged treatment timelines and are prone to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after infusion....
4.
Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, et al.
Clin Exp Med
. 2024 May;
24(1):105.
PMID: 38771501
Chimeric antigen receptor T cell (CAR-T) therapy is an effective treatment for B cell malignancies. A certain fraction of patients, however, experience post-CAR-T relapse, and due to the difficulty of...
5.
Sugimoto M, Yonezawa A, Kanda J, Itohara K, Hira D, Yamagiwa T, et al.
Ther Drug Monit
. 2024 Apr;
46(5):611-618.
PMID: 38648638
Background: Posaconazole is a vital drug to treat and prevent invasive fungal infections. Several factors, such as sex, body weight, total serum proteins, dietary intake, and severe mucositis, affect posaconazole...
6.
Natori D, Ozasa H, Shima Y, Mizumoto C, Suminaga K, Nomizo T, et al.
Mol Clin Oncol
. 2024 Mar;
20(4):33.
PMID: 38476337
The combined occurrence of lung cancer and B-cell lymphoma, such as mucosa-associated lymphoid tissue (MALT) lymphoma, is rare. The efficacy and safety of immune checkpoint inhibitors (ICIs) remain unknown in...
7.
Nakamura N, Mizumoto C, Sugimoto A, Fujimoto M, Ayaki T, Takaori-Kondo A
Rinsho Ketsueki
. 2024 Feb;
65(1):47-51.
PMID: 38311389
T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) has a poor prognosis. Nelarabine has recently shown relatively good results in patients with relapsed or refractory T-ALL/LBL, but requires careful monitoring for neurological complications. A 50-year-old...
8.
Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, et al.
Transplant Cell Ther
. 2024 Jan;
30(4):404-414.
PMID: 38281589
Prolonged hematotoxicity is the most common long-term adverse event in chimeric antigen receptor T cell therapy (CAR-T). To evaluate the impact on prolonged cytopenia of inflammatory status after CAR T...
9.
Kato T, Mizumoto C, Inoue F, Watanabe T, Yamanaka S, Fukuhara S, et al.
Exp Ther Med
. 2023 Dec;
27(1):41.
PMID: 38125353
Methotrexate-related other iatrogenic immunodeficiency-associated lymphoproliferative disorder (MTX-OIIA-LPD) is prone to extranodal involvement but rarely involves the central nervous system (CNS). The present study reports a case of MTX-OIIA-LPD of the...
10.
Jo T, Arai Y, Kitawaki T, Nakamura N, Nishikori M, Mizumoto C, et al.
Bone Marrow Transplant
. 2023 Dec;
59(3):419-421.
PMID: 38110621
No abstract available.